MOG and myeloid sarcoma: Although the international panel did not recommend routine testing of MOG-Ab and did not support the application of the criteria to patients with a better alternative diagnosis (i.e., MS), we have applied the 2023 MOGAD diagnostic criteria to a selected cohort of patients tested for MOG-Abs and found that these 2023 international MOGAD criteria still exhibit high performance.